Drug Database
GE

GEOMATRIX (GEOMATRIX)

✓ Approved

SkyePharma PLC · therapeutic agent

What is GEOMATRIX?

GEOMATRIX is a therapeutic agent developed by SkyePharma PLC. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesGEOMATRIX
CompanySkyePharma PLC
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, SkyePharma PLC

Therapeutic Indications

GEOMATRIX is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresOral appliance application✓ Approved

Related Research Articles

PubMedDrug development and industrial pharmacy2015-04-02

Development and uniform evaluation of ropinirole osmotic pump tablets with REQUIP XL both in vitro and in beagle dogs.

Li Zhiping Z, Yu Fanglin F, Di Zhong Z, Zhao Xiqing X et al.

REQUIP XL, prolonged release formulation of ropinirole hydrochloride (RH) in market, could release ropinirole constantly and showed satisfactory therapeutic effect and good compliance. REQUIP XL was composed of more than 10 kinds of excipients and prepared by Geomatrix technology, which was complex and laborious. The purpose of this study was to obtain a dosage form of RH with similar in vitro release profile and bioequivalence in vivo compared to REQUIP XL. Osmotic pump tablet combined with fast release phase was selected as the delivery system of RH and similar release curves were obtained in different media. The tablets were also administered to beagle dogs and the pharmacokinetic parameters were calculated using a non-compartmental model. Cmax, tmax, mean residence time (MRT), and area under the curve from 0 to 24 h (AUC0-24) were 3.97 ± 0.53 ng/mL, 3.58 ± 0.49 h, 8.29 ± 0.93 h, and 35.20 ± 8.11 ng/mL ċ h for ropinirole osmotic pump tablets (ROPT) and 4.15 ± 1.07 ng/mL, 2.92 ± 0.49 h, 7.84 ± 1.09 h, and 34.34 ± 10.06 ng/mL ċ h for REQUIP XL. The log-transformed mean Cmax and AUC0-24 of ROPT were about 92.15% and 102.49% relative to that of REQUIP XL, respectively. The 90% confidence intervals of Cmax and AUC0-24 for ROPT were 75.69-115.31% and 88.89-122.30%, respectively. So it could be concluded that ROPT was uniform with REQUIP XL both in vitro and in beagles and the release profiles of Geomatrix technology may be obtained by osmotic pump combined with fast release technology.

PMID 25830369
Read full article →
PubMedDrug development and industrial pharmacy2012-05-23

Development and comparative evaluation of in vitro, in vivo properties of novel controlled release compositions of paroxetine hydrochloride hemihydrate as against Geomatrix™ platform technology.

Khatavkar Umesh Nandkumar UN, Shimpi Shamkant Laxman SL, Jayaram Kumar K K, Deo Kishor Dattatraya KD

The objective of this study is to develop, in vitro and in vivo evaluation of novel approaches for controlled release of paroxetine hydrochloride hemihydrate (PHH) in comparison to patented formulation PAXIL CR(®) tablets of GlaxoSmithKline (Geomatrix™ technology). In one of the approaches, hydrophilic core matrix tablets containing 85% of the dose were prepared and further coated with methacrylic acid copolymer to delay the release. An immediate release coating of 15% was given as top coat. The tablets were further optionally coated using ethyl cellulose. In the second approach, hydrophobic matrix core tablets containing metharylic acid copolymer were prepared. In the third approach, PHH was granulated with enteric polymer and further hydrophobic matrix core tablets were prepared. The effect of polymer concentration, level of enteric coating on drug release was evaluated by in vitro dissolution study by varying dissolution apparatus and the rotation speeds. It was found that increase in concentration of high viscosity hydroxypropylmethylcellulose (HPMC) resulted in reduction of the release rate. The drug release was observed to be dependent on the level of enteric coating and ethyl cellulose coating, being slower at increased coating. The release mechanism of PHH followed zero-order shifting to dissolution dependent by the increase of HPMC content. The formulation was stable without change in drug release rate. In vivo study in human volunteers confirmed the similarity between test and innovator formulations. In conclusion, HPMC-based matrix tablets, which were further coated using methacrylic acid copolymer, were found to be suitable for the formulation of single layer-controlled release PHH.

PMID 22607046
Read full article →
PubMedInternational journal of molecular sciences2012-02-09

Oral drug delivery systems comprising altered geometric configurations for controlled drug delivery.

Moodley Kovanya K, Pillay Viness V, Choonara Yahya E YE, du Toit Lisa C LC et al.

Recent pharmaceutical research has focused on controlled drug delivery having an advantage over conventional methods. Adequate controlled plasma drug levels, reduced side effects as well as improved patient compliance are some of the benefits that these systems may offer. Controlled delivery systems that can provide zero-order drug delivery have the potential for maximizing efficacy while minimizing dose frequency and toxicity. Thus, zero-order drug release is ideal in a large area of drug delivery which has therefore led to the development of various technologies with such drug release patterns. Systems such as multilayered tablets and other geometrically altered devices have been created to perform this function. One of the principles of multilayered tablets involves creating a constant surface area for release. Polymeric materials play an important role in the functioning of these systems. Technologies developed to date include among others: Geomatrix(®) multilayered tablets, which utilizes specific polymers that may act as barriers to control drug release; Procise(®), which has a core with an aperture that can be modified to achieve various types of drug release; core-in-cup tablets, where the core matrix is coated on one surface while the circumference forms a cup around it; donut-shaped devices, which possess a centrally-placed aperture hole and Dome Matrix(®) as well as "release modules assemblage", which can offer alternating drug release patterns. This review discusses the novel altered geometric system technologies that have been developed to provide controlled drug release, also focusing on polymers that have been employed in such developments.

PMID 22312236
Read full article →
PubMedParkinsonism & related disorders2010-02-04

Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies.

Onofrj M M, Bonanni L L, De Angelis M V MV, Anzellotti F F et al.

Our review summarizes the five main studies conducted to evaluate the efficacy and pharmacokinetics of ropinirole prolonged release (PR) in Parkinson's disease (PD). The PR formulation was developed with Geomatrix coating technology in order to obtain constant pharmacokinetics throughout 24 hours. The areas under the curve were not significantly different from those observed with similar doses of ropinirole immediate-release (IR) formulation, administered 3 times a day, but concentration fluctuations were less for ropinirole PR (2-fold vs 5-fold). The efficacy study of the PR versus IR formulations showed non-inferiority of the PR formulation, similar tolerability and feasibility of overnight switches, and indicated that the optimal doses of ropinirole in patients with de novo PD is in the range of 8-12 mg/day. The efficacy study in PD patients with motor fluctuations treated with L-dopa showed that adding ropinirole PR significantly reduced "off" time and increased "on" time in comparison with placebo. The study with ropinirole as an add-on to L-dopa showed a reduced incidence of dyskinesias.

PMID 20123565
Read full article →
PubMedTalanta2007-04-30

Direct LD-FTMS detection of mineral-associated PAHs and their influence on the detection of co-existing amino acids.

Yan Beizhan B, Stoner Daphne L DL, Scott Jill R JR

Polycyclic aromatic hydrocarbon (PAH) compounds and amino acids (AAs) are both ubiquitous throughout the universe and can be co-located in mineral matrices (e.g., meteorites); therefore, co-detection of PAHs and AAs associated with terrestrial and extra-terrestrial minerals is of interest. Nine PAH compounds representing four chemical classes of PAH (unsubstituted, acetyl-, amino-, and nitro-substituted) were applied onto the surface of quartz, plagioclase, olivine, and ilmenite mineral standards and analyzed using laser desorption/ionization Fourier transform mass spectrometry (LD-FTMS). Mass-to-charge peaks derived from PAH compounds were detected from the surfaces of all minerals evaluated. All PAH compounds were detected in the positive ion mode, whereas only nitro-substituted PAH compounds were detected in negative ion mode. In this and earlier studies, the ability to directly detect mineral-associated AAs by LD-FTMS was dependent on the mineral geomatrix. On iron-bearing minerals AAs appeared as highly fragmented ions in the spectra or were not detectable; however, the addition of the PAH chrysene enabled the ionization and detection of AAs threonine and histidine by LD-FTMS. Thus, for mineral systems such as meteorites, interstellar dust particles, soils, and sediments, the co-detection of AAs associated with PAHs by LD-FTMS is feasible.

PMID 19071666
Read full article →
PubMedChemical & pharmaceutical bulletin2005-09-06

Modulation of Tenoxicam release from hydrophilic matrix: modulator membrane versus rate-controlling membrane.

El-Nabarawi Mohamed Ahmed MA

This paper describes the preparation of two layered device comprising of tenoxicam containing layer and a drug free membrane layer based on Geomatrix Technology. Our device based on bilaminated films which produced by a casting/solvent evaporation technique. The drug-hydroxypropyl methylcellulose (HPMC) layer was covered by drug free membrane layer composed of a mixture of different ratios of HPMC and ethyl cellulose (EC). The prepared devices were evaluated for thickness, weight, drug content uniformity, water absorption capacity and in-vitro drug release. The films were also evaluated for appearance, smoothness and transparency. The influence of drug free membrane layer composition and thickness on the drug release pattern was studied on 12 devices (D1 to D12). The results indicate that, the release of drug from HPMC matrixes without the drug free membrane layer was fast and follows diffusion controlled mechanism. The release of drug from the devices D1, D4, D9 and D12 follow the same mechanism, while the release of drug from other devices become linear with time (zero order) and extended for long time especially when thickness and the ratio of EC was increased in the drug free membrane layer. From this study it is concluded that, changing the geometry of drug layer by addition of drug free membrane layer and changing its composition and thickness plays an important role in determining whether the drug free membrane layer is rate-controlling or modulator membrane. Hence it can facilitate the development of different pharmaceutical products with different release pattern.

PMID 16141572
Read full article →

+10 more articles available with a free account

Sign up free to view all articles →

Ask about GEOMATRIX